Celldex Therapeutics (CLDX, Financial) experienced a notable stock movement with a 5.01% increase in its share price, reaching $28.10. The trading volume was 325,224 shares, with a turnover rate of 0.49% and a fluctuation of 4.35%.
Recent financial reports reveal that Celldex generated $3.19 million in revenue, with a net loss of $42.12 million and an earnings per share (EPS) of -$0.64. The company's gross profit stood at $2.41 million, and it has a price-to-earnings (P/E) ratio of -10.89.
Institutional ratings show strong confidence in Celldex, with 83% of the 12 participating brokerages recommending a buy, while 17% suggest holding. No institutions have advised selling the stock.
In the broader biotechnology sector, where Celldex operates, there was an overall increase of 0.63%. Other notable performers in the sector included Neurosense Therapeutics, Protagenic Therapeutics, and Cero Therapeutics Holdings, which showed significant gains. Cyclerion Therapeutics, Outlook Therapeutics, and Tc Biopharm also demonstrated high activity with turnover rates of 1031.77%, 252.32%, and 66.14%, respectively. Neurosense Therapeutics, Silexion Therapeutics, and Protagenic Therapeutics exhibited large fluctuations of 86.60%, 79.26%, and 78.75%.
Celldex Therapeutics is a biopharmaceutical company specializing in developing and commercializing immunotherapy technologies and targeted cancer biologics. It conducts clinical trials for breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its product pipeline includes Varlilumab, CDX-301, CDX-1140, CDX-0159/Anti-KIT, and CDX-527.
